Company / Cash & Equivalents
Rein Therapeutics, Inc. Cash & Equivalents History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$12.9M
FY2025
5-year range
$3.6M / $17.3M
FY2021-FY2025
Trend
-25.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 9 years, ranging from $4M in FY2021 to $17M in FY2024.
Based on SEC 10-K filings.
$13M in FY2025 with a 5-year CAGR of +12.8%.
Declined from $17M to $13M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +35.3%
- 5-Year CAGR
- +12.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +12.8%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 25.7% year-over-year.
- Peak cash & equivalents was recorded in FY2024.
- Lowest cash & equivalents in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -9.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $12.9M | -25.7% |
| FY2024 | $17.3M | +0.0% |
| FY2023 | $17.3M | +233.3% |
| FY2022 | $5.2M | +44.3% |
| FY2021 | $3.6M | -48.9% |
| FY2020 | $7.0M | +32.7% |
| FY2019 | $5.3M | -50.1% |
| FY2018 | $10.6M | -10.4% |
| FY2017 | $11.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026